melatonin neurim
rad neurim pharmaceuticals eec sarl - melatonin - sleep initiation and maintenance disorders - psycholeptics - melatonin neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
circadin
neurim pharmaceuticals (1991) ltd, israel - melatonin - tablets prolonged release - melatonin 2 mg - melatonin - melatonin - short-term treatment for primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.
circadin
neurim pharmaceuticals (1991) ltd, israel - melatonin - tablets prolonged release - melatonin 2 mg - melatonin - short-term treatment for primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.
slenyto 1 mg
neurim pharmaceuticals (1991) ltd, israel - melatonin - tablets prolonged release - melatonin 1 mg - melatonin - slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (asd) and/or smith-magenis syndrome, where sleep hygiene measures have been insufficient.
slenyto 5 mg
neurim pharmaceuticals (1991) ltd, israel - melatonin - tablets prolonged release - melatonin 5 mg - melatonin - slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (asd) and/or smith-magenis syndrome, where sleep hygiene measures have been insufficient.
circadin
rad neurim pharmaceuticals eec sarl - melatonin - sleep initiation and maintenance disorders - psycholeptics - circadin is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
slenyto
rad neurim pharmaceuticals eec sarl - melatonin - sleep initiation and maintenance disorders; autistic disorder - psycholeptics - slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (asd) and / or smith-magenis syndrome, where sleep hygiene measures have been insufficient.
circadin 2mg modified-release tablets
flynn pharma ltd - melatonin - modified-release tablet - 2mg
circadin
pharmacy retailing (nz) ltd t/a healthcare logistics - melatonin 2mg; ; - modified release tablet - 2 mg - active: melatonin 2mg excipient: ammonio methacrylate copolymer calcium hydrogen phosphate dihydrate colloidal silicon dioxide lactose monohydrate magnesium stearate purified talc - monotherapy for the short term treatment (up to 13 weeks) of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.
vigisom
pharmacy retailing (nz) ltd t/a healthcare logistics - melatonin 2mg; ; - modified release tablet - 2 mg - active: melatonin 2mg excipient: ammonio methacrylate copolymer calcium hydrogen phosphate dihydrate colloidal silicon dioxide lactose monohydrate magnesium stearate purified talc - monotherapy for the short term treatment (up to 13 weeks) of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.